SciELO - Scientific Electronic Library Online

 
vol.48 issue2Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysisCryptococcal cerebellitis in no-VIH patient author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Colombia Médica

On-line version ISSN 1657-9534

Abstract

OSPINA, Fabio E et al. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report. Colomb. Med. [online]. 2017, vol.48, n.2, pp.88-93. ISSN 1657-9534.

Case description:

Five-year-old female patient with hereditary hemorrhagic telangiectasia.

Clinical Findings:

Deterioration of cardiopulmonary function with higher oxygen requirements secondary to pulmonary arteriovenous shunts, epistaxis.

Treatment and Outcome:

The patient was treated with the monoclonal antibody bevacizumab, which inhibits the vascular endothelial growth factor, with good clinical outcome.

Clinical Relevance:

Hereditary hemorrhagic telangiectasia is an autosomal dominant disorder characterized by arteriovenous malformations in different organs, making its clinical presentations varied. Systemic therapeutic options for a generalized disease are limited. The monoclonal antibody bevacizumab, seems to be a good option in this disorder. Although reported as successful in adult population, its use in pediatric population has not yet been reported. Here we report the use of bevacizumab in a 5-year-old female patient with hereditary hemorrhagic telangiectasia, showing clinical benefits and good outcome.

Keywords : Telangiectasia Hereditary Hemorrhagic; Bevacizumab; Osler-Rendu-Weber Disease; Pediatrics.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )